Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2022.2695
Abstract: Importance In patients with severe aortic valve stenosis at intermediate surgical risk, transcatheter aortic valve replacement (TAVR) with a self-expanding supra-annular valve was noninferior to surgery for all-cause mortality or disabling stroke at 2 years.… read more here.
Keywords: aortic valve; intermediate risk; surgery; valve ... See more keywords
Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.18318
Abstract: Key Points Question Are there racial differences in receipt and duration of conservative management (ie, active surveillance or watchful waiting) among veterans with low-risk and intermediate-risk prostate cancer? Findings In this cohort study of 51 543… read more here.
Keywords: risk; conservative management; intermediate risk; low risk ... See more keywords
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.15991
Abstract: Key Points Question Is there an association between dynamic measurable residual disease, treatment, and outcomes among adults with intermediate-risk acute myeloid leukemia? Findings In this registry-based cohort study that included 549 younger patients (aged 14-60… read more here.
Keywords: risk acute; myeloid leukemia; measurable residual; residual disease ... See more keywords
Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.3470
Abstract: Importance Among patients who undergo the 21-gene assay (21-GA), 39% to 67% receive an intermediate risk result and may receive ambiguous treatment guidance. The 70-gene signature assay (70-GS) may be associated with physicians’ treatment decisions… read more here.
Keywords: risk; treatment; breast cancer; intermediate risk ... See more keywords
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.7605
Abstract: Importance The ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate. Objective To explore the optimal therapy for patients with intermediate-risk AML after first… read more here.
Keywords: consolidation chemotherapy; intermediate risk; consolidation; hct ... See more keywords
Association of Total Thyroidectomy or Thyroid Lobectomy With the Quality of Life in Patients With Differentiated Thyroid Cancer With Low to Intermediate Risk of Recurrence.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA surgery"
DOI: 10.1001/jamasurg.2021.6442
Abstract: Importance Owing to the good prognosis of differentiated thyroid cancer (DTC), guidelines recommend total thyroidectomy (TT) or thyroid lobectomy (TL) as surgical treatment for DTC with low to intermediate risk of recurrence. However, the association… read more here.
Keywords: cancer; quality life; risk recurrence; intermediate risk ... See more keywords
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25961
Abstract: We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23‐55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers. At diagnosis, 70% of patients were asymptomatic. With… read more here.
Keywords: waldenstr macroglobulinemia; risk; immunotherapy; high risk ... See more keywords
Race‐specific prostate cancer outcomes in a cohort of low and favorable‐intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4802
Abstract: Previous research exploring the role of race on prostate cancer (PCa) outcomes has demonstrated greater rates of disease progression and poorer overall survival for African American (AA) compared to Caucasian American (CA) men. The current… read more here.
Keywords: low favorable; prostate cancer; intermediate risk; race ... See more keywords
Advanced percutaneous management in acute pulmonary embolism: Real‐world challenges and opportunities
Sign Up to like & getrecommendations! Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30164
Abstract: Acute pulmonary embolism (PE) is a significant cause of cardiovascular morbidity and mortality and requires prompt diagnosis and treatment. Early diagnosis and management are paramount as most deaths from acute PE occur within the first… read more here.
Keywords: management; intermediate risk; pulmonary embolism; risk ... See more keywords
Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33789
Abstract: BACKGROUND Adavosertib (AZD1775) is an inhibitor of the Wee1 kinase. The authors conducted a phase 1b trial to evaluate the safety of adavosertib in combination with definitive chemoradiotherapy for patients with newly diagnosed, intermediate-risk/high-risk, locally… read more here.
Keywords: combination; phase; risk; high risk ... See more keywords
A Hidden Epidemic of “Intermediate Risk” Oropharynx Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Laryngoscope Investigative Otolaryngology"
DOI: 10.1002/lio2.316
Abstract: Oropharyngeal squamous cell carcinoma (OPSCC) incidence is rapidly increasing in the United States and around the world, driven in large part by infection with the human papillomavirus (HPV). HPV associated OPSCC (HPV+OPSCC) has been shown… read more here.
Keywords: risk oropharynx; intermediate risk; hidden epidemic; epidemic intermediate ... See more keywords